Navigation Links
NeurogesX Reports First Quarter 2009 Results
Date:5/7/2009

the NDA; NeurogesX' plans, and expected timing, with regard to seeking partnerships for its product candidates; the sufficiency of cash resources to fund the NeurogesX' operations through at least December 31, 2009; the ability to secure funding through commercial partnerships; expectations regarding expenses and cash burn rate; expectations with respect to seeking funding; the potential markets for NeurogesX' product candidates; and the expected benefits of NeurogesX' product candidates. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to, positive results in clinical trials, or the recommendation of the CHMP for MAA approval, may not be sufficient to obtain FDA or European regulatory approval; any regulatory approvals which are received may offer more limited indications than anticipated; unexpected expenses; inability to enter into or obtain adequate funding under commercial or other strategic partnerships; NeurogesX' product candidates may have unexpected adverse side effects or inadequate therapeutic efficacy; physician or patient reluctance to use Qutenza or NGX-1998, if approved, or the inability of physicians to obtain sufficient reimbursement for such procedures; potential alternative therapies; maintaining adequate patent or trade secret protection without violating the intellectual property rights of others; and other difficulties or delays in, clinical development, obtaining regulatory approval, market acceptance and commercialization of NeurogesX' product candidates and the advantages of NeurogesX' product candidates over other pain therapies. For further information regarding these and other risks related to NeurogesX' business, investors should consult NeurogesX' filings with the Securities and Exchange Commission.


                                     NEUROGESX, INC.
                             
'/>"/>
SOURCE NeurogesX, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. NeurogesX to Hold Conference Call to Discuss First Quarter 2009 Financial Results
2. NeurogesX Presents Two Posters at 61st Annual American Academy of Neurology Annual Meeting
3. NeurogesX to Hold Conference Call to Discuss Fourth Quarter and Year-End 2008 Financial Results and European Regulatory Update
4. NeurogesX Qutenza(TM) (NGX-4010) Receives Positive Committee Recommendation in European Union
5. NeurogesX to Present at 11th Annual BIO CEO & Investor Conference
6. NeurogesX to Present at Rodman & Renshaw 10th Annual Healthcare Conference
7. NeurogesX Reports Third Quarter 2008 Results
8. NeurogesX to Report Third Quarter 2008 Financial Results
9. NeurogesX Submits NDA for NGX-4010 Dermal Capsaicin Patch for Treatment of Postherpetic Neuralgia (PHN)
10. NeurogesX Responds to EMEAs Day 120 Questions
11. NeurogesX to Present at Morgan Stanley Global Healthcare Unplugged Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... PrimeSource Building Products, Inc., a leading ... to support their communication needs with the ... conferencing platform GlobalMeet powered by SoundConnect. The solution ... SoundConnect delivers award winning “results driven” business class ... be utilizing GlobalMeet powered by SoundConnect ...
(Date:8/28/2014)... Whitehouse Laboratories is excited to announce ... PTI Inspection Systems that will enable it ... art leak testing method development and validation programs using ... As part of this agreement, Whitehouse Labs has taken ... Instrument developed and manufactured by PTI. The HVLD ...
(Date:8/27/2014)... Austin, TX (PRWEB) August 27, 2014 ... $6 million in Series B funding and secured Otter ... and investment capital will accelerate commercialization of GGI’s Agriplier™ ... multiple crop types. , “Since our first meeting, ... commitment to the biological product space,” said Alan Sobba, ...
(Date:8/27/2014)... Livermore, California (PRWEB) August 27, 2014 ... (LLNL), through Lawrence Livermore National Security ... million to develop and deliver a state-of-the-art laser ... Beamlines facility (ELI Beamlines), under construction in the ... design performance, the laser system, called the " ...
Breaking Biology Technology:PrimeSource Chooses SoundConnect as Collaboration Provider 2Whitehouse Labs Renews Partnership with PTI Inspection Systems 2Whitehouse Labs Renews Partnership with PTI Inspection Systems 3Green & Grow Inc. Secures $6M Series B Funding from Otter Capital 2Green & Grow Inc. Secures $6M Series B Funding from Otter Capital 3LLNL Synchs up with ELI Beamlines on Timing System 2LLNL Synchs up with ELI Beamlines on Timing System 3
... Feb. 28 InterMune, Inc.,(Nasdaq: ITMN ) ... Officer of InterMune, will present at Susquehanna,s Second ... on March 5, 2008,at 2:30 p.m. EST., ... presentation, investors and other,interested parties may log on ...
... from Antibody Technology (up 28%); Third Consecutive Quarter of ... Growth in Food Pathogen Testing Business, NEWARK, Del., ... - reported that total revenues for the quarter ended,December ... over the fourth,quarter of 2006. Revenues for the 2007 ...
... BioCryst,Pharmaceuticals (Nasdaq: BCRX ) today announced that ... be released on Tuesday, March 4,2008. At 8:30 a.m. ... to discuss the financial results and provide an update ... will be led by Jon,P. Stonehouse, BioCryst,s Chief Executive ...
Cached Biology Technology:InterMune to Present at the SIGnificant Options in Healthcare Conference 2Strategic Diagnostics Reports Fourth Quarter and Full-Year Financial Results 2Strategic Diagnostics Reports Fourth Quarter and Full-Year Financial Results 3Strategic Diagnostics Reports Fourth Quarter and Full-Year Financial Results 4Strategic Diagnostics Reports Fourth Quarter and Full-Year Financial Results 5Strategic Diagnostics Reports Fourth Quarter and Full-Year Financial Results 6Strategic Diagnostics Reports Fourth Quarter and Full-Year Financial Results 7Strategic Diagnostics Reports Fourth Quarter and Full-Year Financial Results 8Strategic Diagnostics Reports Fourth Quarter and Full-Year Financial Results 9Strategic Diagnostics Reports Fourth Quarter and Full-Year Financial Results 10Strategic Diagnostics Reports Fourth Quarter and Full-Year Financial Results 11Strategic Diagnostics Reports Fourth Quarter and Full-Year Financial Results 12BioCryst Pharmaceuticals to Announce Fourth Quarter and Fiscal Year 2007 Financial Results on March 4, 2008 2BioCryst Pharmaceuticals to Announce Fourth Quarter and Fiscal Year 2007 Financial Results on March 4, 2008 3
(Date:8/28/2014)... of marine protected areas is needed to protect fish ... investigators from the Wildlife Conservation Society and other organizations, ... the largest numbers of species, often at the expense ... functions. , Many vital ecological functions of ... are food for millions of people. This study ...
(Date:8/28/2014)... (Maximizing Access to Research Careers) Program has announced the ... Genetics from October 18 22, 2014 in San ... the entry of students, post doctorates and scientists from ... community and to encourage the participation of young scientists ... year MARC conferred 16 awards totaling $29,600., The FASEB ...
(Date:8/28/2014)... to Research Careers) Program has announced the travel ... 27th Annual Mouse Molecular Genetics Conference from September ... California. These awards are meant to promote ... from underrepresented groups into the mainstream of the ... of young scientists at the Genetics Society of ...
Breaking Biology News(10 mins):Study finds marine protected areas inadequate for protecting fish and ocean ecology 2
... has on aquatic insects in mountain lakes can be ... study completed by U.S. Forest Service and University of ... online issue of the journal Freshwater Biology where they ... practices now in use in California mountain lakes where ...
... Wildlife Conservation Society thanks The Brain Tumor Foundation and ... in performing a brain scan on a gorilla at ... dozens of wildlife veterinarians, zookeepers, and medical personnel from ... MRI Unit, a 48-foot-long MRI facility on wheels that ...
... HOLE, MATiny, toxic protein particles severely disrupt neurotransmission and ... separate studies by Marine Biological Laboratory (MBL) researchers have ... beta, which has long been known to accumulate and ... "These small particles that haven,t aggregated into plaquesthese ...
Cached Biology News:Study assesses impact of fish stocking on aquatic insects 2Gorilla gets MRI at Bronx Zoo 2Gorilla gets MRI at Bronx Zoo 3Tiny but toxic: MBL researchers discover a mechanism of neurodegeneration in Alzheimer's disease 2
... cultured in RPMI 1640 medium with 2 mM ... growth. In order to keep the antigens ... acetone-methanol. The cells are arrayed on a ... wells surface specifically treated to enhance cellular attachment ...
Mouse polyclonal antibody to REXO4 - XPMC2 prevents mitotic catastrophe 2 homolog (Xenopus laevis)...
... StabilCoat Plus Microsphere/Microarray Stabilizer is an aqueous ... and other non-toxic chemicals in a PBS ... 7.4. This product contains a combination ... a preservative. StabilCoat Plus Stabilizer provides ...
... ABgene's Protein Purification Plates are designed ... SDS-PAGE gels. The 96-well plates feature two ... ends of each well. The wells remain ... with buffer, during which time the protein ...
Biology Products: